Nomura Asset Management Co. Ltd. Sells 273,958 Shares of Boston Scientific Corporation $BSX

Nomura Asset Management Co. Ltd. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 23.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 877,065 shares of the medical equipment provider’s stock after selling 273,958 shares during the quarter. Nomura Asset Management Co. Ltd. owned 0.06% of Boston Scientific worth $94,206,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BSX. Brighton Jones LLC lifted its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Kingsview Wealth Management LLC raised its position in Boston Scientific by 2.6% during the first quarter. Kingsview Wealth Management LLC now owns 6,735 shares of the medical equipment provider’s stock valued at $679,000 after purchasing an additional 172 shares in the last quarter. Private Advisor Group LLC lifted its stake in Boston Scientific by 10.8% during the first quarter. Private Advisor Group LLC now owns 38,274 shares of the medical equipment provider’s stock worth $3,861,000 after purchasing an additional 3,734 shares during the last quarter. Formidable Asset Management LLC bought a new stake in Boston Scientific during the first quarter worth $206,000. Finally, Kestra Private Wealth Services LLC boosted its holdings in shares of Boston Scientific by 21.0% in the 1st quarter. Kestra Private Wealth Services LLC now owns 40,130 shares of the medical equipment provider’s stock valued at $4,048,000 after purchasing an additional 6,977 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock opened at $102.73 on Monday. The firm has a market capitalization of $152.30 billion, a price-to-earnings ratio of 54.94, a PEG ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $99.72 and its 200-day moving average price is $102.56. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 175,782 shares of company stock valued at $17,742,314 in the last ninety days. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Barclays lifted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.